Literature DB >> 9216015

Cystoid macular edema as an initial symptom of inflammatory orbital pseudotumor.

H Igarashi1, S Igarashi, S Ishiko, K Fukui, A Yoshida.   

Abstract

We report a patient with pseudotumor with cystoid macular edema (CME). The initial finding in our case was only CME with a bilateral visual acuity decrease to 20/25. Approximately 3 months later, the visual acuity dropped to light perception in the right eye and 20/200 in the left eye. Computed tomography scan revealed a mass in the right orbital apex and band-shaped enhancement in the cavernous sinus and along the upper margin of the petrous bone. However, no mass was found intraoperatively, and a biopsy specimen of the bulging levator muscle showed polymorphonuclear leukocyte infiltration. The CME resolved postoperatively. The tumor also seemed to resolve; however, after 1 year, the tumor recurred and invaded the brain tissue. A temporal lobectomy revealed widespread inflammatory cell infiltration. To ensure early diagnosis, pseudotumor should be considered in patients with CME of which the cause is uncertain.

Entities:  

Mesh:

Year:  1997        PMID: 9216015     DOI: 10.1159/000310798

Source DB:  PubMed          Journal:  Ophthalmologica        ISSN: 0030-3755            Impact factor:   3.250


  3 in total

Review 1.  Treatment of cystoid macular edema with non-steroidal anti-inflammatory drugs and corticosteroids.

Authors:  T J Wolfensberger; C P Herbort
Journal:  Doc Ophthalmol       Date:  1999       Impact factor: 2.379

Review 2.  Inflammatory pseudotumor of the cavernous sinus and skull base.

Authors:  Todd McCall; Daniel R Fassett; George Lyons; William T Couldwell
Journal:  Neurosurg Rev       Date:  2006-03-25       Impact factor: 3.042

3.  Inflammatory myofibroblastic tumour of the skull base.

Authors:  Jean-Philippe Maire; Sandrine Eimer; François San Galli; Valérie Franco-Vidal; Sigolène Galland-Girodet; Aymeri Huchet; Vincent Darrouzet
Journal:  Case Rep Otolaryngol       Date:  2013-02-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.